RNS Number : 6635D MaxCyte, Inc. 23 June 2023 Result of AGM Rockville, MD , June 23 , 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as
RNS Number : 4553D MaxCyte, Inc. 21 June 2023 Publication of Annual Report ROCKVILLE, MD , June 21, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and
RNS Number : 0358D MaxCyte, Inc. 16 June 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing Gaithersburg, Maryland - 16 June 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 3691B MaxCyte, Inc. 02 June 2023 MaxCyte to Participate in Upcoming Investor Conferences Rockville, MD , June 2, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative
ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development
RNS Number : 2294B MaxCyte, Inc. 01 June 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 June 2023: MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
RNS Number : 0855Z MaxCyte, Inc. 11 May 2023 MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2023 ROCKVILLE, MD , May 11, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
RNS Number : 0134Z MaxCyte, Inc. 11 May 2023 MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance ROCKVILLE, MD , May 11, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support
RNS Number : 6706Y MaxCyte, Inc. 09 May 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing Gaithersburg, Maryland - 9 May 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
